| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma
|
Chen, Y.P.
|
|
|
26 |
1 |
p. 205-211
|
artikel
|
| 2 |
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial
|
Élez, E.
|
|
|
26 |
1 |
p. 132-140
|
artikel
|
| 3 |
Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency
|
Maeda, H.
|
|
|
26 |
1 |
p. 211-216
|
artikel
|
| 4 |
Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort †
|
Wang, A.
|
|
|
26 |
1 |
p. 221-230
|
artikel
|
| 5 |
A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenib
|
Rechsteiner, M.
|
|
|
26 |
1 |
p. 246-248
|
artikel
|
| 6 |
A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors
|
Tolcher, A.W.
|
|
|
26 |
1 |
p. 58-64
|
artikel
|
| 7 |
Challenges in combining novel molecularly targeted agents in cancer medicine
|
Yap, T.A.
|
|
|
26 |
1 |
p. 9-11
|
artikel
|
| 8 |
Chemotherapy benefit for ‘ER-positive’ breast cancer and contamination of Nonluminal subtypes—waiting for TAILORx and RxPONDER
|
Sun, Z.
|
|
|
26 |
1 |
p. 70-74
|
artikel
|
| 9 |
Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance
|
Khoja, L.
|
|
|
26 |
1 |
p. 33-39
|
artikel
|
| 10 |
Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades
|
Das, L.C.
|
|
|
26 |
1 |
p. 198-205
|
artikel
|
| 11 |
Corrections to “P–0271 Concurrent oral UFT and pelvic irradiation as neoadjuvant chemoradiation for operable rectal cancer: a phase II study”
|
Helmy, S.
|
|
|
26 |
1 |
p. 254
|
artikel
|
| 12 |
Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) † † This manuscript does not refer to patients undergoing allogeneic hematopoietic stem cell transplantation. These patients are subject to a separate AGIHO guideline [1].
|
Maschmeyer, G.
|
|
|
26 |
1 |
p. 21-33
|
artikel
|
| 13 |
Differences among young adults, adults and elderly chronic myeloid leukemia patients
|
Castagnetti, F.
|
|
|
26 |
1 |
p. 185-192
|
artikel
|
| 14 |
Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK ‘borderline’-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies
|
Ilie, M.I.
|
|
|
26 |
1 |
p. 238-244
|
artikel
|
| 15 |
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study
|
Van Cutsem, E.
|
|
|
26 |
1 |
p. 149-156
|
artikel
|
| 16 |
Editorial Board
|
|
|
|
26 |
1 |
p. ii-iii
|
artikel
|
| 17 |
Estimates of benefits and harms of prophylactic use of aspirin in the general population
|
Cuzick, J.
|
|
|
26 |
1 |
p. 47-57
|
artikel
|
| 18 |
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy †
|
Lindner, J.L.
|
|
|
26 |
1 |
p. 95-100
|
artikel
|
| 19 |
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials
|
Sorich, M.J.
|
|
|
26 |
1 |
p. 13-21
|
artikel
|
| 20 |
Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth
|
Kobayashi, Y.
|
|
|
26 |
1 |
p. 156-161
|
artikel
|
| 21 |
High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study †
|
Necchi, A.
|
|
|
26 |
1 |
p. 167-172
|
artikel
|
| 22 |
Immune biomarkers of anti-EGFR monoclonal antibody therapy
|
Trivedi, S.
|
|
|
26 |
1 |
p. 40-47
|
artikel
|
| 23 |
Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial
|
Cella, D.
|
|
|
26 |
1 |
p. 179-185
|
artikel
|
| 24 |
instructions to authors
|
|
|
|
26 |
1 |
p. 255-261
|
artikel
|
| 25 |
Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?
|
Abali, H.
|
|
|
26 |
1 |
p. 245
|
artikel
|
| 26 |
Letter to the editor concerning ‘Elevated serum antibodies against insulin-like growth factor-binding protein-2 allow detecting early-stage cancers: evidences from glioma and colorectal carcinoma studies’
|
Hassan, W.A.
|
|
|
26 |
1 |
p. 252-253
|
artikel
|
| 27 |
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
|
Tobin, N.P.
|
|
|
26 |
1 |
p. 81-88
|
artikel
|
| 28 |
Nutritional assessment in overweight and obese patients with metastatic cancer: does it make sense?
|
Gioulbasanis, I.
|
|
|
26 |
1 |
p. 217-221
|
artikel
|
| 29 |
Obesity and the outcome of young breast cancer patients in the UK: the POSH study
|
Copson, E.R.
|
|
|
26 |
1 |
p. 101-112
|
artikel
|
| 30 |
Pharmacokinetic interaction involving fenofibrate and everolimus
|
Mir, O.
|
|
|
26 |
1 |
p. 248-249
|
artikel
|
| 31 |
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer
|
Yamada, Y.
|
|
|
26 |
1 |
p. 141-148
|
artikel
|
| 32 |
Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer
|
Cao, K.I.
|
|
|
26 |
1 |
p. 89-94
|
artikel
|
| 33 |
Phase I trials in oncology: a new era has started
|
Postel-Vinay, S.
|
|
|
26 |
1 |
p. 7-9
|
artikel
|
| 34 |
Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy
|
Bylicki, O.
|
|
|
26 |
1 |
p. 231-237
|
artikel
|
| 35 |
Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial †
|
Klingbiel, D.
|
|
|
26 |
1 |
p. 126-132
|
artikel
|
| 36 |
Pushing the boundaries of somatic copy-number variation detection: advances and challenges
|
Sathirapongsasuti, J.F.
|
|
|
26 |
1 |
p. 11-12
|
artikel
|
| 37 |
Renal impairment and late toxicity in germ-cell cancer survivors
|
Lauritsen, J.
|
|
|
26 |
1 |
p. 173-178
|
artikel
|
| 38 |
Reply to the letters to the editor ‘Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma’ by Diwakar et al.
|
Schilling, B.
|
|
|
26 |
1 |
p. 250-251
|
artikel
|
| 39 |
Reply to the letters to the editor ‘Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma’ by Schilling et al.
|
Davar, D.
|
|
|
26 |
1 |
p. 251-252
|
artikel
|
| 40 |
Reply to the Letter to the Editor ‘Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?’ by Abali et al.
|
Sugihara, K.
|
|
|
26 |
1 |
p. 245-246
|
artikel
|
| 41 |
Reply to the letter to the editor ‘Measured and estimated glomerular filtration rate for carboplatin dose calculation’ by Cathomas et al.
|
Bertelli, G.
|
|
|
26 |
1 |
p. 249-250
|
artikel
|
| 42 |
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy
|
Sheri, A.
|
|
|
26 |
1 |
p. 75-80
|
artikel
|
| 43 |
Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data
|
Favero, F.
|
|
|
26 |
1 |
p. 64-70
|
artikel
|
| 44 |
Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing
|
Sun, J.-M.
|
|
|
26 |
1 |
p. 161-166
|
artikel
|
| 45 |
Table of Contents
|
|
|
|
26 |
1 |
p. iv-vi
|
artikel
|
| 46 |
thanks to referees 2014
|
|
|
|
26 |
1 |
p. 1-6
|
artikel
|
| 47 |
Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer
|
Treilleux, I.
|
|
|
26 |
1 |
p. 120-125
|
artikel
|
| 48 |
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA †
|
Krop, I.E.
|
|
|
26 |
1 |
p. 113-119
|
artikel
|
| 49 |
90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas
|
Bouabdallah, K.
|
|
|
26 |
1 |
p. 193-198
|
artikel
|
Tijdschrift beschrijving